RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 12-Week Treatment with LY2409021 Significantly Lowers HbA1C and Is Well Tolerated in Patients with Type 2 Diabetes Mellitus
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 16
SP 16
OP 17
DO 10.1177/155989771216007
UL http://mdc.sagepub.com/content/12/16/16.abstract
AB The glucagon receptor antagonist LY2409021 (LY) substantially lowers HbA1C without severe hypoglycemia or weight gain in type 2 diabetes mellitus (T2DM) patients. In a double-blind, randomized, placebo-controlled, Phase 2 study researchers examined the margin between LY efficacy and safety by comparing mean changes in HbA1C and liver aminotransferases at 3 dose levels.